Biota targets the sniffles

By Kate McDonald
Monday, 11 August, 2008

Melbourne's Biota Holdings (ASX: BTA) has commenced dosing in an early stage trial of BTA798, an orally delivered inhibitor of human rhinovirus (HRV), a major cause of the common cold.

The UK based trial is aimed at evaluating BTA798 as a prophylactic against HRV infection in 200 health volunteers, who will receive a placebo or one of three dose levels before exposure to an experimental rhinovirus infection.

The drug candidate is designed to bind to clefts on the surface of the virus's capsid shell and interfere with attachment to receptors.

Results are expected in April next year.

Content from other channels on our network

Deakin University launches metal resources research centre

Dragos introduces OT-native cybersecurity AI

Construction begins on south‍-‍west WA advanced manufacturing hub

Newcastle carbon capture plant opens

Accenture acquires Dragos and increases OT cybersecurity offering

Detoxifying 'super fungi' may recover critical minerals

Training centre opens to improve alloy lifecycle

Water utilities know where AI fits — but can the foundations carry it?

FIFA World Cup to generate 156 tonnes of plastic waste

Collaboration provides NZ's largest smart water meter upgrade

Breaking the biofilm shield that harbours foodborne pathogens

Second cell-cultured food under assessment by FSANZ

Indigenous food culture and responsible seafood celebrated

Shaking up whey protein manufacturing technique

Danone to acquire Made Group

Biota targets the sniffles

Australia's first cases of H5 avian influenza confirmed

AusBiotech partners with Tenmile

Australian CDC issues update in wake of Ebola outbreak

Content from other channels on our network